Welcome to our dedicated page for Lemaitre Vasculr SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for LeMaitre Vascular, Inc. (NASDAQ: LMAT), a Delaware-incorporated medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Through these filings, investors can review the company’s formal disclosures on operations, financial condition, risk factors, and governance.
LeMaitre’s SEC submissions include annual reports on Form 10-K and quarterly reports on Form 10-Q, which present detailed financial statements, segment information, and discussions of risks such as competition, supplier dependence, regulatory compliance for devices and tissue products, international operations, product defects or recalls, litigation, and intellectual property protection. Current reports on Form 8-K, such as those referenced in the provided materials, disclose events like quarterly financial results, board decisions, and other material developments.
The company also uses its filings to describe capital markets activities, including the listing of its common stock on The Nasdaq Global Market under the symbol LMAT, the existence of convertible senior notes, dividend declarations, and share repurchase authorizations. These documents complement the non-GAAP metrics discussed in press releases by providing reconciliations and additional context for measures such as organic sales growth, adjusted margins, and EBITDA.
On Stock Titan, LeMaitre’s filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy documents like 10-Ks and 10-Qs, highlight important changes from prior periods, and clarify the implications of 8-K disclosures. Users can also review insider-related filings such as Forms 3, 4, and 5, where available, to track transactions by directors and officers. This combination of raw filings and AI-generated insights allows readers to understand LMAT’s regulatory record and financial reporting more efficiently.
LeMaitre Vascular reported a director receiving additional common shares through equity awards. On 12/12/2025, the director acquired 5 shares of common stock in each of two transactions at a stated price of $0 per share, reflecting the release of dividend equivalent rights tied to earlier stock awards. After these transactions, reported beneficial ownership entries were 5,317 and 5,322 common shares held directly. Related dividend equivalent right positions were reduced to zero, with any fractional shares settled in cash at vesting.
LeMaitre Vascular Inc. reported that one of its directors acquired common stock through the release of dividend equivalent rights on 12/12/2025. Two transactions each delivered 5 shares of common stock at an exercise price of $ 0 per share, following the vesting of restricted stock unit and performance stock unit awards originally granted on 12/12/2022.
Each dividend equivalent right is the economic equivalent of one share of common stock, and any fractional shares were settled in cash, resulting in a final balance of zero dividend equivalent rights. After these transactions, the director reported direct holdings of 3,460 and 3,465 common shares, plus 181 shares held indirectly through a spouse.
LeMaitre Vascular reported an equity grant to its Senior Vice President of Operations. On 12/10/2025, the executive received 1,177 shares of common stock as a restricted stock unit award at a stated price of $0, bringing direct beneficial ownership of common stock to 4,660 shares.
The executive also received a stock option covering 7,222 shares of common stock at an exercise price of $83.66 per share, expiring on 12/10/2032. The restricted stock units vest 25% on 12/1/2026, with the remainder vesting in equal annual installments over the following three years, and the issuer may withhold shares to satisfy tax obligations. The option vests over four years, with 25% vesting on the first anniversary of the grant date and the balance in equal annual installments over the next three years.
LeMaitre Vascular Inc's chief financial officer reported receiving new equity awards in the company’s stock. On 12/10/2025, the officer acquired 1,177 shares of common stock at a stated price of $0, bringing direct ownership to 2,398 common shares.
The filing also shows a new stock option grant for 7,222 shares with an exercise price of $83.66 and an expiration date of 12/10/2032. The 1,177-share award is structured as restricted stock units that vest 25% on 12/1/2026, with the rest vesting in equal annual installments over the following three years. The option vests over four years at 25% on the first anniversary of the grant date listed, with the balance vesting in equal annual installments over the next three years.
LeMaitre Vascular Inc. disclosed that its president and director received new equity awards. On 12/10/2025, the insider acquired 1,694 shares of common stock as a restricted stock unit award at a price of $0, bringing total common stock beneficially owned to 23,091 shares held directly.
The insider was also granted a stock option for 10,400 shares of common stock with an exercise price of $83.66, expiring on 12/10/2032. The restricted stock units vest 25% on 12/1/2026, with the remainder vesting in equal annual installments over three years, and include share withholding to cover taxes. The option vests 25% on the first anniversary of 12/01/2025, with the balance vesting in equal annual installments over the following three years.
LeMaitre Vascular Inc reported that a company director received new equity awards in the form of common stock and stock options. On 12/10/2025, the director acquired 533 shares of common stock through a restricted stock unit award at a price of $0 per share, bringing direct beneficial ownership to 62,340 shares.
The disclosure also shows stock options covering 3,431 shares of common stock with an exercise price of $83.66 and an expiration date of 12/10/2030. The restricted stock units vest 33 1/3% on 12/1/2026, with the remainder vesting in equal annual installments over the next two years, while the options vest over three years at 33 1/3% on the first anniversary of 12/01/2025, with the balance vesting in equal annual installments over the following two years.
LeMaitre Vascular reported that one of its directors received new equity awards. On 12/10/2025 the director was granted 533 restricted stock units of common stock at a price of
The restricted stock units vest 33 1/3% on
LeMaitre Vascular reported insider equity transactions by its Senior Vice President, Operations on a Form 4. On 12/06/2025, 2 shares of common stock were acquired at $0 per share upon the release of dividend equivalent rights, bringing direct holdings before tax withholding to 3,712 shares. Also on that date, 69 shares were disposed of at $84.53 per share as shares withheld by the issuer to satisfy tax withholding obligations from previously awarded restricted stock units, resulting in 3,643 common shares owned directly.
The report also shows several acquisitions of dividend equivalent rights on 12/04/2025 that accrued on restricted stock unit and performance share unit awards originally granted on 12/11/2021, 12/12/2022, 12/8/2023, and 12/6/2024. Each dividend equivalent right is stated to be the economic equivalent of one share of LeMaitre Vascular common stock and to vest proportionately with the related awards.
LeMaitre Vascular, Inc. (LMAT)11/21/2025, the reporting person exercised a stock option to buy 7,500 shares of common stock at an exercise price of $37.29 per share, as shown in Table II. These shares, reported in Table I, were acquired and increased the director’s directly owned common stock holdings to 64,801 shares following the transaction. The option, originally granted on 12/02/2020 and fully vested and exercisable, was due to expire on 12/02/2025 and shows 0 derivative securities remaining from this grant after the exercise.
LeMaitre Vascular, Inc. (LMAT) Chairman and CEO, who is also a director, reported an insider transaction on 11/20/2025. He exercised a stock option to buy 2,681 shares of common stock at an exercise price of $41.02 per share, converting a derivative position into directly owned stock. After this exercise, he directly beneficially owns 1,665,984 shares of LeMaitre Vascular common stock.
In addition, 21,300 shares are held indirectly through the “LeMaitre Irrevocable Life Insurance Trust of 2025” for the benefit of his child or children. He disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest. The option that was exercised covered 2,681 shares, was fully vested and exercisable, and now shows 0 derivative securities remaining from that grant.